Our Team

James W. Weis

James Weis was founding President of the MIT Biotechnology Group and is currently the founding CEO of Hatch.Bio Labs, an incubator space dedicated to supporting life sciences startups, and a Partner at Nest.Bio Ventures, a venture firm that takes a uniquely international and holistic approach to developing, funding, and commercializing next-gen technologies.

Nina is a senior in Biological Engineering at MIT. She has been involved in the MIT Media Lab's Community Biotechnology Initiative since 2017 and was previously an officer in the MIT Biotech Group's Investment Initiative. Nina has interned in pharmaceutical R&D and strategy at GSK, and was a 2019 summer analyst at ClearView Healthcare Partners.

Patrick has been a medical device entrepreneur and investor for over 25 years. He is currently President and CEO of SanaHeal, Inc., a clinical-stage medical device company. He was previously founder and CEO of Smart Therapeutics (acquired by Boston Scientific) & Bioabsorbable Therapeutics (acquired by Multi Cell Corporation). He also holds 9 issued patents.

Cami is a senior in Biology and Computer Science at MIT. She has been involved with the group Angels group since 2018 and with the MIT Biotech Group (MBG) since 2017. Cami has worked with New England Biolabs developing NGS tools, .406 Ventures, and in this past summer worked as an analyst within the Life Sciences sector of Navigant.

Wan Li Zhu is Co-Founder and Managing Partner of Suffolk Technologies, a venture capital firm investing in ConTech, PropTech, and InfraTech startups affiliated with construction leader Suffolk. He was previously a Partner at Fairhaven Capital, a Boston-based VC that has invested over $430M in enterprise software and deep tech. Wan Li founded MIT Alumni Angels, which has backed over 100 MIT-affiliated startups in technology and life sciences. Prior to venture capital, he held product and marketing roles at Microsoft. Wan Li holds an MBA from Harvard Business School and Bachelor's and Master's degrees from MIT in Computer Science.

Roman Fleck, PhD, MBA, is an MIT-trained biotechnology executive with over two decades of experience in pharmaceutical R&D, venture investment, and company leadership. He serves on the boards of Iktos, HDAX Therapeutics, and Adularia, and previously chaired Omniose. Dr. Fleck co-founded and led Janpix (acquired by Centessa Pharmaceuticals) and was a Partner at Medicxi Ventures, investing in companies such as GlycoVaxyn (GSK), Novocure (NASDAQ: NVCR), and Micromet (Amgen). He began his career at Boehringer Ingelheim and earned his PhD in Organic Chemistry from the Massachusetts Institute of Technology (MIT) and his MBA from New York University’s Stern School of Business.

Phoebe is a junior in Computer Science at MIT, and was previously a director of the investment initiative of the MIT Biotech Group (MBG), and has been part of the group since 2017. She worked in immunology research at the Irvine Lab in the Koch Institute for Integrative Cancer Research at MIT and as a data scientist at Optum, a healthcare information technology firm.

Kristen Overly is a senior in Biological Engineering at MIT. She has served as the Undergraduate President of the MIT Biotech Group, and was previously a director of the Angels group. She consulted for Remora Therapeutics, worked on JPMorgan Chase’s Healthcare Equity Capital Markets team, and will be joining Back Bay Life Sciences.

Tyler is CEO and co-founder of Soap Payments, an AI-native payments and compliance platform for high-risk verticals, and previously co-founded Jock MKT, a real-money fantasy sports exchange active in over 30 states. He is an active Venture Scout for the Alumni Ventures Sports Fund, and has also held roles at Antler VC as an Entrepreneur in Residence and began his career in economic consulting at Analysis Group. Tyler earned his MBA from MIT’s Sloan School of Management.